Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 8/20 | 0.41 |
| ▸ | GHSR | Q92847 | 2/20 | 0.38 |
| ▸ | TP53 | P04637 | 5/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2118235 | 0.85 | MAPT (0.41) | MAPTGHSRTP53SMN1; SMN2MEN1 | |
| SCHEMBL2122228 | 0.81 | ACLY (0.48) | MAPTALDH1A1 | |
| SCHEMBL2119347 | 0.81 | KMT2A (0.50) | MAPTGHSRTP53SMN1; SMN2MEN1 | |
| SCHEMBL2118075 | 0.77 | CYP3A4 (0.43) | MAPTGHSRTP53SMN1; SMN2KMT2A | |
| SCHEMBL2117662 | 0.75 | POLB (0.42) | MAPTGHSRTP53MEN1KMT2A | |
| SCHEMBL2121533 | 0.75 | MEN1 (0.45) | MAPTGHSRMEN1KMT2AALDH1A1 | |
| SCHEMBL2119833 | 0.74 | MAPT (0.52) | MAPTTP53SMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL2119311 | 0.73 | ALDH1A1 (0.46) | MAPTGHSRTP53SMN1; SMN2MEN1 | |
| SCHEMBL2117167 | 0.73 | CYP2D6 (0.42) | MAPTGHSRSMN1; SMN2MEN1KMT2A | |
| SCHEMBL2119240 | 0.73 | GHSR (0.42) | MAPTGHSRSMN1; SMN2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120095012-A1 | TOLUIDINE SULFONAMIDES AND THEIR USE | ELARA PHARMACEUTICALS GMBH (DE) | 2012-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120095012-A1 | TOLUIDINE SULFONAMIDES AND THEIR USE | HIF1A, HIF1AN, EGLN3 | MAPT 4747/4885GHSR 1390/4885TP53 249/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.